Group 1: Report Summary - Report research object: Sanxin Medical [17] - Industry: Medical devices [2] - Research date: April 21, 2025 [1] - Receiving personnel: Liu Ming, Director, Vice President, and Secretary of the Board of Directors [17] Group 2: Research Institutions - Institution: Asset management company - Huashang Fund [20] Group 3: Core Views - The policy focus of centralized procurement has shifted from "expanding coverage and reducing prices" to "stabilizing prices and improving quality", which promotes the industry to develop in a standardized and sustainable direction [22] - The company has won bids for major products within the scope of centralized procurement, with obvious price advantages, and is expected to increase market share through "trading price for volume" [22] - The company has built a product system for blood purification in end - stage renal disease, and will continue to enrich product portfolios and expand into related fields [23] Group 4: Centralized Procurement Situation - Policy: The policy focus has shifted from "expanding coverage and reducing prices" to "stabilizing prices and improving quality" [22] - Regional scope: Centralized procurement of hemodialysis products has basically achieved national coverage [22] - Company's situation: The company has won bids for major products, with price advantages, and the new rules have accelerated the domestic substitution of hemodialyzers [22][23] Group 5: Product Introduction - Hemodialysis filtration products: The company has a product system covering hemodialysis and hemodialysis filtration, and will continue to enrich the product group and expand into related fields [23] - Wet - membrane dialyzer products: In 2024, the company obtained the first domestic brand registration certificate for wet - membrane dialyzers, which are well - received in the market [25] - Dialysis indwelling needle products: The company's self - developed product has the first domestic brand registration certificate, won the first - place winning bid in centralized procurement, but its widespread clinical application still needs time [26] - PTA high - pressure balloon dilation catheter products: The company has obtained the product registration certificate, and it has been selected for a 27 - province centralized procurement project, expected to achieve "trading price for volume" [27] - Needle - free syringe products: The company has developed a medical needle - free syringe, which can eliminate patients' fear of needles and improve drug absorption efficiency, and will be iteratively innovated [28] Group 6: Overseas Business - In 2024, the company's overseas business revenue was 274.12 million yuan, a year - on - year increase of 39.70%. The company completed product registrations in some countries and is promoting certification in other markets [29] - The company will expand the scope of overseas self - held licenses and focus on emerging markets such as Southeast Asia, South America, and Africa [29]